Relay Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenue: | |||
| License and other revenue | $10,007 | $25,546 | $1,381 |
| Total revenue | 10,007 | 25,546 | 1,381 |
| Operating expenses: | |||
| Research and development expenses | $319,089 | $330,018 | $246,355 |
| Change in fair value of contingent consideration liability | (13,206) | (6,422) | (11,677) |
| General and administrative expenses | 76,592 | 74,950 | 65,978 |
| Total operating expenses | 382,475 | 398,546 | 300,656 |
| Loss from operations | (372,468) | (373,000) | (299,275) |
| Other income: | |||
| Interest income | 34,746 | 31,045 | 8,786 |
| Other income (expense) | 14 | (18) | (20) |
| Total other income, net | 34,760 | 31,027 | 8,766 |
| Net loss | $(337,708) | $(341,973) | $(290,509) |
| Net loss per share, basic and diluted | $(2.36) | $(2.79) | $(2.59) |
| Weighted average shares of common stock, basic and diluted | 142,867,844 | 122,576,527 | 112,233,649 |
| Other comprehensive (loss) income: | |||
| Unrealized holding (loss) gain | (795) | 10,224 | (9,332) |
| Total other comprehensive (loss) income | (795) | 10,224 | (9,332) |
| Total comprehensive loss | $(338,503) | $(331,749) | $(299,841) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.